“Palivizumab Prophylaxis in Preterm Infants Does Not Decrease Recurrent Wheezing or Asthma but Maternal Smoking with Aeroallergen Sensitization Increases Asthma Risk: A 10-Year Follow-Up Study”

https://pubmed.ncbi.nlm.nih.gov/38116923

The 10-year follow-up study found that palivizumab prophylaxis in preterm infants did not reduce the incidence of subsequent recurrent wheezing or asthma, but maternal smoking with aeroallergen sensitization was significantly correlated with asthma development.